L'Oréal recently announced the acquisition of a 10% stake in Galderma, a leading pure-play dermatology company and one of the world’s largest players in injectable aesthetics This strategic move signifies L'Oréal's deeper commitment to the fast-growing medical aesthetics market, complementing its established expertise in skincare and beauty.
This investment is furthered strengthened by a new strategic scientific partnership between L'Oréal and Galderma. This collaboration aims to leverage the unique strengths of both companies - Galderma’s extensive portfolio of dermatological solutions, and L'Oréal's expertise in skin biology, diagnostic tools and evaluation methods.
Commenting on the acquisition, Nicolas Hieronimus, Chief Executive Officer of L'Oréal, said, "This strategic investment marks an ambitious step for L'Oréal, and true to our mantra of ‘seize what is starting’ it allows us to explore partnering in the fast-growing aesthetic market, a key adjacency to our own pure beauty play.” He emphasised L'Oréal's full support of Galderma's management and strategy, adding that the company respects Galderma’s independence and is confidence in its long-term growth potential.
As a global leader in the beauty sector, L'Oréal’s strategy has increasingly leaned towards a holistic beauty approach that integrates advanced diagnostic tools, high-performance topical products, consumer products, and aesthetic treatments. This comprehensive strategy aims to deliver a new combined level of performance, addressing the full spectrum of skin ageing – from correction and repair to prevention anticipation and interception.
Galderma under the leadership of Chief Executive Officer, Flemming Ørnskov, M.D., MPH, welcomed L'Oréal as a strong long-term partner. The company is fully supportive of this transaction and strategic scientific partnership.
Founded in 1981, Galderma operates in around 90 countries, providing science-based brands and services across the dermatology spectrum. The company’s expertise in dermo-cosmetics and injectable treatments, including hyaluronic acid fillers and neuromodulators, has made it a key player in the aesthetics industry.
For L’Oréal, the acquisition aligns with its mission of leading innovation in beauty. With over 115 years of experience, L’Oréal’s portfolio includes 37 international brands, backed by a global network of over 90,000 employees. The company’s 20 research centers across 11 countries, along with a dedicated team of over 4,000 scientists, underscore its commitment to inventing the future of beauty and becoming beauty tech powerhouse.
Comments